Skip to main content
. Author manuscript; available in PMC: 2011 Jun 8.
Published in final edited form as: Biochemistry. 2010 Jun 8;49(22):4583–4600. doi: 10.1021/bi100068u

Figure 5.

Figure 5

Illustration of the hAGRP(87-132) antagonist pharmacology at the wild type (WT), E61K, D90N, Y157S, and C271R hMC4Rs. The MTII ligand is a full agonist at the WT hMC4R and a partial agonist at the E61K, D90N, Y157S, and C271R hMC4Rs relative to non-receptor dependent maximal stimulation by the forskolin control compound which is defined as 1.0 on the Y-axis.